What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline

Description: The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:

- Addiction
- Allergy
- Alzheimer's Disease
- Anthrax
- Asthma
- Campylobacter Infection
- Chlamydia
- Croup
- Dengue Fever
- Diabetes
- Ebola
- Epstein-Barr Virus
- Enterotoxigenic Escherichia coli
- Helicobacter Pylori
- Hepatitis
- Herpesvirus
- Hookworm
- Hypertension
- HIV/AIDS
- Leishmaniasis
- Malaria
- MRSA Infection
- Multiple Sclerosis
- Obesity
- Parainfluenza Virus Type 3
- Parkinson's Disease
- Plague
- Respiratory Syncytial Virus
- Ross River Virus
- Shigellosis
- Smoking
- Stroke
- Tuberculosis
- West Nile Virus

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be.

Alison Sahoo has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on
the emerging vaccine activities of the following companies

Acambis plc
ACE BioSciences
AFFiRIS
ALK-Abello A/S
Allergy Therapeutics
Bavarian Nordic A/S
Baxter Healthcare
Celldex Therapeutics
Crucell
Cytos Biotechnology
GlaxoSmithKline
Hawaii Biotech
Intercell
Medimmune
Merck & Co. Inc
Mymetics
Nabi Biopharmaceuticals
Novartis
Opexa Therapeutics
Paladin Labs
Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

Contents:

CHAPTER ONE: EXECUTIVE SUMMARY
Scope and Methodology
Overview
Emerging Vaccines and Forecasts
The Global Market for Emerging Vaccines
CHAPTER TWO: INTRODUCTION TO VACCINES
A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Bacteria-Based Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccination
Vaccine Approval Process
Trends Driving the Vaccines Market

CHAPTER THREE: EMERGING VACCINES
Introduction
Emerging Vaccines by Disease Area
Addiction
Smoking
Allergy
Alzheimer’s Disease
Anthrax
Asthma
Campylobacter Infection
Chlamydia
Croup
Dengue Fever
Diabetes
Ebola
Epstein-Barr Virus
Enterotoxigenic Escherichia coli
Heart Attack
Helicobacter Pylori
Hepatitis
Hepatitis C
Hepatitis E
Herpesvirus
Hookworm
Hypertension
HIV/AIDS
Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
Parainfluenza Virus Type 3
Parkinson’s Disease
Plague
Respiratory Syncytial Virus
Ross River Virus
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
Global Market for Emerging Vaccines
Emerging Vaccines Market Segment Forecasts
Addiction
Allergies
Alzheimer's Disease
Anthrax
Asthma
Campylobacter Infection
Chlamydia
Croup
Dengue Fever
Diabetes
Ebola
EBV Infection
ETEC Infection
Heart Attack
H. Pylori Infection
Hepatitis C and E
Herpesvirus Infection
Hookworm
Hypertension
HIV/AIDS
Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
PIV-3 Infection
Parkinson's Disease
Plague
RSV Infection
Ross River Virus Infection
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FIVE: ISSUES AND TRENDS
New Vaccine Technologies
DNA Vaccination
Innovative Delivery Systems
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches
Funding Shortfalls

CHAPTER SIX: COMPANY PROFILES
Acambis plc
History and Lines of Business
Emerging Vaccine Activities
Financial Information
ACE BioSciences
History and Lines of Business
Emerging Vaccine Activities
Financial Information
AFFIRIS
History and Lines of Business
Emerging Vaccine Activities
Financial Information
ALK-Abello A/S
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Allergy Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Bavarian Nordic A/S
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Baxter Healthcare
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Celldex Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Crucell
History and Lines of Business
Emerging Vaccine Activities
Financial Information
GlaxoSmithKline
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Hawaii Biotech
History and Lines of Business
Emerging Vaccine Products
Financial Information
Intercell
History and Lines of Business
Emerging Vaccine Products
Financial Information
Medimmune
History and Lines of Business
Emerging Vaccine Products
Financial Information
Merck & Co. Inc
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Mymetics
History and Lines of Business
Emerging Vaccine Products
Financial Information
Nabi Biopharmaceuticals
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Novartis
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Opexa Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Paladin Labs
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Sanofi Pasteur
History and Lines of Business
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Status of Emerging Vaccines by Disease

CHAPTER TWO: INTRODUCTION TO VACCINES
Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2008
Table 2-2: Vaccine-Preventable Diseases, December 2009
Table 2-3: VAERS Table of Reportable Events Following Vaccination

CHAPTER THREE: EMERGING VACCINES
Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines
Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines
Table 3-1: Emerging Vaccines by Disease and Stage of Testing
Figure 3-3: Comparative Severity Ranking of Addiction
Figure 3-4: Comparative Severity Ranking of Allergy
Figure 3-5: Comparative Severity Ranking of Alzheimer’s Disease
Figure 3-6: Comparative Severity Ranking of Anthrax
Figure 3-7: Comparative Severity Ranking of Asthma
Figure 3-8: Comparative Severity Ranking of Campylobacter Infection
Figure 3-9: Comparative Severity Ranking of Chlamydia
Figure 3-10: Comparative Severity Ranking of Croup
Figure 3-11: Comparative Severity Ranking of Dengue Fever
Figure 3-12: Comparative Severity Ranking of Diabetes
Figure 3-13: Comparative Severity Ranking of Ebola
Figure 3-14: Comparative Severity Ranking of EBV
Figure 3-15: Comparative Severity Ranking of ETEC
Figure 3-16: Comparative Severity Ranking of Heart Attack
Figure 3-17: Comparative Severity Ranking of H. Pylori Infection
Figure 3-18: Comparative Severity Ranking of Hepatitis C and E
Figure 3-19: Comparative Severity Ranking of Herpesvirus Infection
Figure 3-20: Comparative Severity Ranking of Hookworm
Figure 3-21: Comparative Severity Ranking of Hypertension
Figure 3-22: Comparative Severity Ranking of HIV/AIDS
Figure 3-23: Comparative Severity Ranking of Leishmaniasis
Figure 3-24: Comparative Severity Ranking of Malaria
Figure 3-25: Comparative Severity Ranking of MRSA Infection
Figure 3-26: Comparative Severity Ranking of Multiple Sclerosis
Figure 3-27: Comparative Severity Ranking of Obesity
Figure 3-28: Comparative Severity Ranking of PIV-3 Infection
Figure 3-29: Comparative Severity Ranking of Parkinson's Disease
Figure 3-30: Comparative Severity Ranking of Plague
Figure 3-31: Comparative Severity Ranking of RSV Infection
Figure 3-32: Comparative Severity Ranking of Ross River Virus Infection
Figure 3-33: Comparative Severity Ranking of Shigellosis
Figure 3-34: Comparative Severity Ranking of Stroke
Figure 3-35: Comparative Severity Ranking of Tuberculosis
Figure 3-36: Comparative Severity Ranking of West Nile Virus Infection

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
Table 4-1: World Market for Emerging Vaccines by Type, 2009-2020
Table 4-2: World Market for Emerging Vaccines by Type, 2009-2020
Table 4-3: World Addiction Vaccine Market 2009-2020
Table 4-4: World Allergy Vaccine Market 2009-2020
Table 4-5: World Alzheimer's Disease Vaccine Market 2009-2020
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2860947/">http://www.researchandmarkets.com/reports/2860947/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6IIX8Y</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 4600 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise-wide:</td>
<td>USD 8400</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World